A pilot study: do physiotherapy joint and muscle movement techniques improve forced expiratory volume in one second (FEV1) in adults with cystic fibrosis?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN90285133

Enrollment

Registered

2007-09-28

Start date

2006-12-14

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional, Metabolic, Endocrine: Cystic fibrosis Nutritional, Metabolic, Endocrine Cystic fibrosis

Interventions

The Patient Advocate for Cystic Fibrosis, Royal Brompton & Harefield NHS Trust, the Senior Research Fellow in Physiotherapy, Dr Jennifer Pryor, and Senior Medical Consultant of the Department of Cysti

Eligibility

Inclusion criteria

Inclusion criteria: Added June 2008: 1. Reported postural changes, stiffness, discomfort and/or pain of musculoskeletal origin in the thoracic spine or chest wall 2. Diagnosis of cystic fibrosis (confirmed by genotype or a sweat sodium concentration of >70mmol/l or sweat chloride of >60mmol/l) 3. Sixteen years of age or over 4. Patients in a stable clinical state with lung function at the time of entry that is within 10% of the mean of the last two recordings (separated by at least one month). 5. Forced Expiratory Volume in 1 second (FEV1) =30% predicted at time of entry to the study

Exclusion criteria

Exclusion criteria: Added June 2008: 1. Evidence of a current respiratory exacerbation (worsening) as defined by Thornton et al. 2004 2. Cor pulmonale (right heart failure) 3. Low bone density (Z score < -3)(WHO Study Group 1994) 4. Previous history of spontaneous fractures 5. Past history of spinal fracture or other known arthopathic (joint) or spinal disease process 6. Currently undergoing musculoskeletal (physiotherapy, chiropractic or osteopathic) treatment 7. Pregnancy 8. Inability to give consent 9. Current enrolment in another research trial

Design outcomes

Primary

Measure	Time frame
For the treatment group, outcome measures will be taken 30 minutes after treatment. For the control group these will be taken 15 to 30 minutes after arrival for assessment. The primary outcome measure will be forced expiratory volume in one second.	—

Secondary

Measure	Time frame
1. Other measures of lung function: forced vital capacity, peak expiratory flow rate, residual volume as a percent of total lung capacity 2. Modified shuttle test, monitoring oxygen saturation and heart rate and Borg CR10 scale of perceived exertion 3. Visual analogue scale for pain: a qualitative subjective assessment using a 10-centimeter scale 4. The Cystic Fibrosis Quality of Life Questionnaire, section one: physical functioning (Questionnaire I) 5. Flexi curve measurements of posture in standing 6. Chest wall excursion measurements using a tape measure for the circumference of the chest wall at axilla (armpit) and xiphisternal (lower chest) level 7. A questionnaire using a series of visual analogue scales with room for individual comment (Questionnaire II)	—

Measure

Time frame

1. Other measures of lung function: forced vital capacity, peak expiratory flow rate, residual volume as a percent of total lung capacity 2. Modified shuttle test, monitoring oxygen saturation and heart rate and Borg CR10 scale of perceived exertion 3. Visual analogue scale for pain: a qualitative subjective assessment using a 10-centimeter scale 4. The Cystic Fibrosis Quality of Life Questionnaire, section one: physical functioning (Questionnaire I) 5. Flexi curve measurements of posture in standing 6. Chest wall excursion measurements using a tape measure for the circumference of the chest wall at axilla (armpit) and xiphisternal (lower chest) level 7. A questionnaire using a series of visual analogue scales with room for individual comment (Questionnaire II)

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026